WCG Insights Home » Case Studies » Overcoming Enrollment Challenges: Patients with Ulcerative Colitis
Most Recent Flipbooks
Psoriatic Arthritis – Enrollment Assistant Support for Studies with Difficult-to-Recruit Patients
Accurate Pain Reporting for Painful Diabetic Neuropathy
WCG Analgesic Solutions found that patients could better report their pain intensity and discriminate between active drug and placebo using APR (accurate pain reporting) training.
Overcoming Recruitment Challenges in Difficult-to-Recruit Populations — An Inside Look at Vaccines
By the Numbers: Six Challenges to Enrollment, One Customized Solution
How WCG ThreeWire Rescued an Under-performing Phase II Constipation Drug Study
WCG ThreeWire Rescue for Data Entry in a Solid Tumor Program
How a Top Pharma Company Successfully Enrolled for a MDD Study
ThreeWire was able to quickly review charts at the 48 sites, leading to 121 consents and 69 enrolled subjects. These efforts contributed 34.5% of all enrollments.
How a Sponsor Secured 200 High-Performing PI's in a New TA in Just 5 Days
Global Osteoarthritis Program facing FDA Safety Concerns
Finding an Agile PV Partner for Early-Stage Clinical Development
Rescuing Two Global Immuno-Oncology Trials with Contracts & Budgets
Partnering for the Future: Rescuing Contracts & Budgets for 10 Global Phase II & III Studies
OhioHealth Case Study
Dissatisfied with its electronic IRB research management solution, OhioHealth Research & Innovation Institute searched for a solution to improve compliance, efficiency, customer service, and cost.
Recruitment Case Study for Osteoarthritis Pain Program
WCG ThreeWire Recruitment Success: 70% of Total Randomization
Study Marketing for Medical Device Sleep Study - US
Enrollment Services Phase III Oncology Drug Study - US & Europe
Case Study: Study Marketing for Prostate Cancer Study - US
How Roche Optimized its Global Safety Reporting Process for Clinical Trials
Roche recognized several major challenges that its CTSP 2.0 system needed to address.
Bringing the Power of Genetics to a Rare Disease Gene Therapy Program